Jonathan Young - Jun 1, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Stock symbol
AKRO
Transactions as of
Jun 1, 2021
Transactions value $
-$80,151
Form type
4
Date filed
6/2/2021, 04:06 PM
Next filing
Jul 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$80.2K -3.06K -1.83% $26.24 164K Jun 1, 2021 Direct F1, F2
holding AKRO Common Stock 20K Jun 1, 2021 By EA Irrevocable Trust F3
holding AKRO Common Stock 20K Jun 1, 2021 By CM Irrevocable Trust F3
holding AKRO Common Stock 20K Jun 1, 2021 By JL Irrevocable Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated September 28, 2020 as amended on November 23, 2020, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.73 to $26.635, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.